This news comes just one day after Vivani announced plans to spin off its neurostimulation business to focus on its GLP-1 implants. The company also announced full enrollment in LIBERATE-1, achieved in just four weeks after the first enrollment. It expects top-line results available in mid-2025.

Alameda, California-based Vivani initiated its LIBERATE-1 trial at two centers in Australia at the end of 2024. The study will evaluate the miniature GLP-1 implant in obese and overweight subjects.

This study follows FDA approval for an investigational new drug (IND) application for the company’s implant in June 2024.